代设计揭示了超分子-药物结合物的分子域关系
Matthew J Sis1, Dongping Liu1, Isabella Allen1
1Department of Chemical & Biomolecular Engineering, University of Notre Dame, Notre Dame, Indiana 46556, United States.
Biomacromolecules
|June 13, 2024
概括
超分子-药物联合体 (sPDCs) 自组装成纳米纤维水凝,用于药物输送. 材料特性取决于分子设计中的药物和成分之间的相互作用.
科学领域:
- 生物材料科学 生物材料科学
- 超分子化学 超分子化学
- 药物输送系统 药物输送系统
背景情况:
- 超分子-药物合物 (sPDC) 是设计用于自组装成纳米纤维水凝的单组分前药物材料.
- 这些材料提供了大质量高效和特定地点的治疗剂传递的潜力.
- 了解sPDC中的结构-属性关系对于优化其设计和功能至关重要.
研究的目的:
- 调查如何通过基片段对sPDCs的疏水域进行修改会影响自组装和材料特性.
- 阐明药物和域中超分子相互作用之间的复杂关系,以及它们对水凝形成,机制和药物释放的影响.
- 探索氨基酸序列和疏水性前药物-基块组成的设计变量.
主要方法:
- 合成9个具有不同氨基酸序列和疏水域的sPDCs.
- 在生理条件下评估水凝形成.
- 描述sPDC水凝的高分子排列,机械性能和药物释放概况.
主要成果:
- 所有合成的sPDC在生理条件下自发形成水凝.
- 在疏水性和基域之间观察到复杂的关系,影响水凝的形成,机械性质和药物释放动力学.
- 与以前的仅含前药设计相比,基片段的加入改变了自我组装途径.
结论:
- sPDC材料特性与整体分子设计密切相关.
- 来自前药物和类领域的结合贡献对于指导新出现的超分子组合的特性至关重要.
- 为了合理设计基于sPDC的先进药物输送系统,需要对这些领域的相互作用进行进一步的研究.
相关概念视频
Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
Drug-Receptor Bonds
2.8K
Drug-receptor bonds are formed through various chemical forces when drugs interact with target cells. Covalent bonds, strong and irreversible, are exemplified by DNA-alkylating anticancer agents that inhibit cell division. However, such irreversible drug binding lacks selectivity and can modify the DNA of the surrounding healthy cells. Covalent binding often contributes to tissue toxicity, as seen with chloroform and paracetamol metabolites binding to the liver, causing hepatotoxicity.
In...
In...
2.8K
Conserved Binding Sites
4.2K
Many proteins’ biological role depends on their interactions with their ligands, small molecules that bind to specific locations on the protein known as ligand-binding sites. Ligand-binding sites are often conserved among homologous proteins as these sites are critical for protein function.
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
Binding sites are often located in large pockets, and if their location on a protein’s surface is unknown, it can be predicted using various approaches. The energetic method computationally...
4.2K
Conservation of Protein Domains Over Different Proteins
10.8K
Protein domains are small structurally independent units that are part of a single amino acid chain. Although these domains are often structurally independent, they may rely on synergistic effects to perform their functions as part of a larger protein. Protein domains may be conserved within the same organism, as well as across different organisms.
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
A limited set of protein domains often duplicate and recombine during evolution. These domains can be organized in different combinations to...
10.8K
Peptide Bonds
74.1K
A peptide bond covalently attaches amino acids through a dehydration reaction. One amino acid's carboxyl group and another amino acid's amino group combine, releasing a water molecule. The resulting bond is the peptide bond. The products that such linkages form are peptides. As more amino acids join this growing chain, the resulting chain is a polypeptide. Each polypeptide has a free amino group at one end. This end has the N-terminal, or the amino-terminal, and the other end has a free...
74.1K
Phase II Conjugation Reactions: Overview
187
Conjugation, a key component of phase II biotransformation reactions, is a vital process in drug detoxification. It involves transferring endogenous substances like glucuronic acid, sulfate, and glycine to drugs or their metabolites formed in phase I reactions. These conjugation reactions, often catalyzed by specific enzymes, transform potentially harmful metabolites into inactive, water-soluble forms easily excreted in urine or bile. By enhancing polarity and eliminating pharmacological...
187


